Fulcrum Therapeutics (NASDAQ:FULC) Posts Earnings Results

Fulcrum Therapeutics (NASDAQ:FULC) released its quarterly earnings results on Tuesday. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.03), Zacks reports.

Fulcrum Therapeutics Stock Performance

Shares of NASDAQ:FULC traded up $0.01 during trading on Thursday, hitting $3.33. The company’s stock had a trading volume of 70,025 shares, compared to its average volume of 451,849. Fulcrum Therapeutics has a fifty-two week low of $2.86 and a fifty-two week high of $13.70. The business has a 50 day moving average price of $4.13 and a two-hundred day moving average price of $4.62. The company has a market capitalization of $179.35 million, a PE ratio of -10.73 and a beta of 2.03.

Analysts Set New Price Targets

FULC has been the subject of several research reports. Royal Bank of Canada reiterated a “sector perform” rating and issued a $4.00 target price on shares of Fulcrum Therapeutics in a report on Thursday, November 14th. HC Wainwright restated a “neutral” rating and set a $4.00 price target on shares of Fulcrum Therapeutics in a research report on Wednesday. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $9.33.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.